Afrezza® INHALE-1 Study in Pediatrics

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 319 participants.

Also called NCT04974528

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 319 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04974528
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04974528. Randomized; no masking; primary purpose treatment. Start 2021-09-29 (actual); primary completion 2024-10-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Afrezza® INHALE-1 Study in Pediatrics
Acronym
INHALE-1
Condition
Diabetes Mellitus, Type 1
Condition
Diabetes Mellitus, Type 2
Intervention (Biological)
Afrezza
Intervention (Biological)
Rapid-acting Insulin Analog
Intervention (Biological)
Basal Insulin
Lead sponsor
Mannkind Corporation (class: industry)
Collaborator
Jaeb Center for Health Research (class: other)

Record details

Record id
cardio:ct-nct04974528
Content hash
d6304d2a6299861afba4f201da43ebe0c021ce32d94b76de82d95ab887364b96